How Many Valeant Pharmaceuticals International, Inc. (NYSE:VRX)'s Analysts Are Bullish?

Armstrong Henry H Associates Inc. now owns 93,753 shares of the specialty pharmaceutical company's stock valued at $1,622,000 after purchasing an additional 295 shares in the last quarter. (NYSE:VRX) has declined 48.51% since December 4, 2016 and is downtrending. It has underperformed by 65.21% the S&P500. Citigroup reported 478,032 shares. Fin Architects holds 0.03% or 10,550 shares. About 10.78M shares traded. State Street Corp invested in 85,799 shares. Strs Ohio reported 135,201 shares. Cornerstone Advisors stated it has 0.12% in Express Scripts Holding Company (NASDAQ:ESRX).

Several large investors have recently made changes to their positions in the stock. The institutional investor held 7.01M shares of the health care company at the end of 2017Q2, valued at $121.29M, up from 1.50M at the end of the previous reported quarter. Following the acquisition, the director now directly owns 94,559 shares in the company, valued at approximately $1,361,649.60. 8,634 are held by Parkside Financial Bank Tru. Integral Derivatives Lc reported 0.01% stake. Tarbox Family Office Incorporated has 1,827 shares. Tocqueville Asset Management L.P. now owns 21,914 shares of the specialty pharmaceutical company's stock valued at $379,000 after acquiring an additional 800 shares in the last quarter. Tyrus Capital Sam holds 127,000 shares. Hendershot Invests owns 75,985 shares or 2.18% of their U.S. portfolio. Credit Agricole S A holds 0% or 36,156 shares in its portfolio. Bancorpsouth has invested 0.05% in Express Scripts Holding Company (NASDAQ:ESRX). About 3.31 million shares traded. It also reduced Ishares Tr (Put) (IYR) stake by 134,000 shares and now owns 166,000 shares.

Among 27 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 6 have Buy rating, 3 Sell and 18 Hold. Express Scripts had 41 analyst reports since July 30, 2015 according to SRatingsIntel. ValueAct Holdings L.P. now owns 17,997,224 shares of the specialty pharmaceutical company's stock worth $198,509,000 after buying an additional 3,002,963 shares in the last quarter. The consensus rating is 2.1, suggesting the market has given up on the stock. The company was downgraded on Monday, October 9 by Raymond James. Gramercy Funds Management Llc who had been investing in Valeant Pharmaceuticals Intl for a number of months, seems to be less bullish one the $6.11B market cap company. The rating was maintained by Stifel Nicolaus with "Buy" on Friday, July 22. Jefferies maintained it with "Buy" rating and $1800 target in Friday, June 9 report.

Lebanese PM Saad al-Hariri revokes his resignation
France's foreign ministry said Friday's meeting was meant to "support the political process (in Lebanon) at a crucial moment". The Lebanese President had said at the time Hariri was being held against his will in Riyadh, a claim Hariri denied.

In other news, Director John Paulson bought 344,216 shares of the firm's stock in a transaction that occurred on Thursday, November 16th. Moors & Cabot Inc. now owns 23,675 shares of the specialty pharmaceutical company's stock valued at $337,000 after buying an additional 8,400 shares during the last quarter. The Stock has YTD (year to date) performance of 18.8 percent. Energy Transfer Partners Lp was raised too. HC Wainwright set a $17.00 price target on Valeant Pharmaceuticals International and gave the stock a "hold" rating in a research report on Wednesday, August 9th. Therefore 22% are positive. Commercial Bank stated it has 0% in Valeant Pharmaceuticals International, Inc. As per Wednesday, March 16, the company rating was maintained by Rodman & Renshaw. 0 analysts gave its stock an Outperform rating. Morgan Stanley maintained it with "Equal-Weight" rating and $39 target in Wednesday, March 16 report. Stifel Nicolaus has "Hold" rating and $90.0 target. On Monday, November 2 the stock rating was downgraded by Goldman Sachs to "Neutral". Piper Jaffray maintained the shares of VRX in report on Friday, September 15 with "Sell" rating. As per Wednesday, March 16, the company rating was maintained by JP Morgan. Valeant Pharmaceuticals International has a 52-week low of $8.31 and a 52-week high of $18.25. (NASDAQ:ZUMZ) to report earnings on December, 7. They expect $0.94 earnings per share, down 25.40% or $0.32 from last year's $1.26 per share. VRX's profit will be $327.66 million for 4.59 P/E if the $0.94 EPS becomes a reality. (NYSE:VRX). Gotham Asset Management Ltd Llc, a New York-based fund reported 823,046 shares.

Investors sentiment decreased to 1.08 in 2017 Q2. The correct version of this story can be viewed at https://www.thelincolnianonline.com/2017/12/03/commonwealth-bank-of-australia-has-2-37-million-position-in-valeant-pharmaceuticals-international-inc-vrx.html. Inc. raised its position in shares of Valeant Pharmaceuticals International by 118.2% during the 3rd quarter. 171.89 million shares or 1.47% more from 169.41 million shares in 2017Q1 were reported. (NYSE:VRX). The Japan-based Tokio Marine Asset Management Commerce Ltd has invested 0.09% in Valeant Pharmaceuticals International, Inc.

Schlumberger Limited (NYSE:SLB) shares ended at $64.73 with 11.95 mln shares exchanging hands. Van Eck holds 0.04% or 414,646 shares. Wells Fargo & Mn invested 0% of its portfolio in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) for 2,000 shares. 236 were reported by Sei Invests. Biglari owns 395,000 shares or 0.55% of their USA portfolio. The Georgia-based Greatmark Investment Prtn has invested 0.18% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Conning owns 340,679 shares.

Related Articles